Eversept Partners, LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001697013
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2025 · 68 positions · Total reported value $1.09B · Top-10 concentration 55.3% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 66.4% · 29 new · 41 cut · 27 exited
Active Share (vs S&P 500): 97.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +11.9% · vs SPY -2.9% · Prev Value $1.87B — last quarter positions weighted by this quarter price moves · ranking
In its Q2 2025 13F filing, Eversept Partners, LP disclosed 68 equity positions with a combined reported value of $1.09B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2025 were NTRA ($134.54M), QQQ ($94.99M), GSK ($86.11M). By sector, the heaviest allocations are Health Care 75.3%, Industrials 10.5%. Versus the prior quarter, allocation shifted toward Industrials (+4.7pp), Other (+3.5pp) and away from Consumer Discretionary (-1.9pp), Health Care (-6.3pp).
Versus the prior quarter, Eversept Partners, LP opened 29 new positions, trimmed 41 and fully exited 27, a turnover rate of 66.4% of positions. The portfolio's overlap with the prior quarter was 68% of names.
The largest new positions opened in Q2 2025 were UNH ($18.95M), ILMN ($18.95M), IQV ($15.38M).
Of the 27 positions fully exited versus the prior quarter, the largest were SPY ($43.02M), NBIX ($18.50M), ALGN ($7.83M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2025)
Fully Exited (vs previous quarter)
Insider Transactions (Form 4)
Latest Eversept Partners, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Eversept Partners, LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 119 US equity positions with a combined value of $1.91B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-108771 (status: Approved), registered 2017-01-11
- Regulatory AUM (Form ADV): $2.65B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 99%, registered investment companies 1%
- Manages 3 private funds, of which 3 hedge funds
- Website: eversept.com
Portfolio Structure
- 119 positions · $1.91B reported value (Q2 2026)
- Top 10 holdings = 46.1% of reported value
- Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 8.2%
- Average position size: $16.06M
Sector Tilt
- Health Care 88.2%
- Real Estate 5.6%
- Industrials 1.3%
- (classified holdings cover 96% of value)
Quarterly Activity
- Q2 2026: 29 new, 42 added, 41 reduced, 27 exited
- 7 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
796.38K | $134.54M | 12.38% | Reduce | |
| 2 |
|
172.20K | $94.99M | 8.74% | Add | |
| 3 |
|
2.24M | $86.11M | 7.92% | Reduce | |
| 4 |
|
2.38M | $56.14M | 5.16% | Add | |
| 5 |
|
510.33K | $49.36M | 4.54% | Add | |
| 6 |
|
1.30M | $42.21M | 3.88% | Add | |
| 7 |
|
99.98K | $38.30M | 3.52% | Reduce | |
| 8 |
|
4.07M | $38.07M | 3.50% | Reduce | |
| 9 |
|
839.28K | $34.58M | 3.18% | Add | |
| 10 |
|
1.90M | $26.60M | 2.45% | Add | |
| 11 |
|
588.90K | $23.27M | 2.14% | Add | |
| 12 |
|
398.73K | $21.64M | 1.99% | Add | |
| 13 |
|
164.47K | $21.34M | 1.96% | Reduce | |
| 14 |
|
6.14M | $20.89M | 1.92% | Reduce | |
| 15 |
|
1.53M | $20.54M | 1.89% | Add | |
| 16 |
|
394.14K | $20.28M | 1.86% | Add | |
| 17 |
|
1.32M | $19.46M | 1.79% | Add | |
| 18 |
|
2.08M | $19.44M | 1.79% | Hold | |
| 19 |
|
60.74K | $18.95M | 1.74% | New | |
| 20 |
|
198.58K | $18.95M | 1.74% | New | |
| 21 |
|
1.05M | $17.65M | 1.62% | Reduce | |
| 22 |
|
838.74K | $17.07M | 1.57% | Add | |
| 23 |
|
59.37K | $17.06M | 1.57% | Add | |
| 24 |
|
155.87K | $16.33M | 1.50% | Reduce | |
| 25 |
|
97.60K | $15.38M | 1.42% | New | |
| 26 |
|
277.32K | $15.33M | 1.41% | Reduce | |
| 27 |
|
1.20M | $11.88M | 1.09% | New | |
| 28 |
|
232.18K | $11.82M | 1.09% | New | |
| 29 |
|
1.21M | $10.82M | 0.99% | Reduce | |
| 30 |
|
1.17M | $10.78M | 0.99% | New | |
| 31 |
|
43.62K | $10.66M | 0.98% | Add | |
| 32 |
|
7.32M | $10.32M | 0.95% | New | |
| 33 |
|
169.64K | $10.01M | 0.92% | Reduce | |
| 34 |
|
64.59K | $9.39M | 0.86% | Add | |
| 35 |
|
414.43K | $7.51M | 0.69% | Add | |
| 36 |
|
18.96K | $7.38M | 0.68% | Add | |
| 37 |
|
13.25K | $6.96M | 0.64% | New | |
| 38 |
|
130.92K | $6.89M | 0.63% | Add | |
| 39 |
|
20.60K | $6.14M | 0.56% | Reduce | |
| 40 |
|
13.69K | $5.55M | 0.51% | New | |
| 41 |
|
392.74K | $5.15M | 0.47% | New | |
| 42 |
|
23.45K | $4.63M | 0.43% | New | |
| 43 |
|
358.83K | $4.47M | 0.41% | Add | |
| 44 |
|
31.50K | $3.25M | 0.30% | Reduce | |
| 45 |
|
325.48K | $3.15M | 0.29% | Reduce | |
| 46 |
|
115.00K | $2.97M | 0.27% | New | |
| 47 |
|
1.99M | $2.78M | 0.26% | Add | |
| 48 |
|
167.28K | $2.71M | 0.25% | Reduce | |
| 49 |
|
697.71K | $2.61M | 0.24% | Hold | |
| 50 |
|
235.99K | $2.32M | 0.21% | Reduce | |
FAQ
What did Eversept Partners, LP buy in 2025-Q2?
In its 2025-Q2 13F filing, Eversept Partners, LP reported 68 equity positions worth $1.09B in aggregate; its largest disclosed positions were NTRA ($134.54M), QQQ ($94.99M), GSK ($86.11M).
How large is Eversept Partners, LP's portfolio?
Eversept Partners, LP reported $1.09B of long equity holdings across 68 positions as of 2025-Q2. Top-10 holdings account for 55.3% of reported value.
What is Eversept Partners, LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.